Mean Platelet Volume as a Prognostic Marker in Thromboembolic Stroke: A Prospective Cross-sectional Study

Abstract Background: Thromboembolic stroke is a leading cause of morbidity and mortality worldwide. Mean platelet volume (MPV), a marker of platelet activation, has been implicated in the pathophysiology of atherosclerosis and ischemic events. Therefore, this study aims to examine the association between peripheral blood MPV and prognosis by comparing the modified Rankin score on the day of presentation with that at 3 months in patients with ischemic stroke. Aim and Objective: To evaluate the prognostic value of MPV in patients with thromboembolic stroke by correlating MPV with the modified Rankin Scale (mRS) at admission and at 3-month follow-up. Materials and Methods: A prospective, cross-sectional, observational study of 90 patients with ischemic stroke at a Medical College hospital in Kota, Rajasthan, India, was conducted between December 2023 and December 2024. MPV was measured at admission, and prognosis was assessed by the change in the mRS score from presentation to 3-month follow-up. Results: MPV values correlated positively with stroke severity and poor functional outcomes. Patients with MPV >10 fL had the worst prognosis, whereas those with MPV 8–10 fL had the best. Statistical significance was observed for MPV with mRS ( P = 0.016), National Institutes of Health Stroke Scale ( P = 0.034), and outcome ( P = 0.0095). Conclusion: Elevated MPV is associated with greater stroke severity and poorer functional outcomes at 90 days, suggesting its utility as a prognostic biomarker in thromboembolic stroke.